Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 6/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 5/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.37 |
| ▸ | NPY1R | P25929 | 3/20 | 0.37 |
| ▸ | NPY4R | P50391 | 3/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10270090 | 0.94 | FURIN (0.39) | FURINFAPMAP1LC3BNPY5RNPY1R | |
| SCHEMBL13002105 | 0.94 | FURIN (0.39) | FURINFAPMAP1LC3BNPY5RNPY1R | |
| SCHEMBL30697716 | 0.93 | FURIN (0.40) | FURINHTTFAPMAP1LC3BNPY5R | |
| SCHEMBL12629537 | 0.92 | FURIN (0.37) | FURINHTTFAPMAP1LC3BNPY5R | |
| SCHEMBL12568288 | 0.92 | FURIN (0.37) | FURINHTTFAPMAP1LC3BNPY5R | |
| SCHEMBL19982142 | 0.90 | MAP1LC3B (0.41) | FAPMAP1LC3B | |
| SCHEMBL16925417 | 0.90 | MAP1LC3B (0.42) | FURINFAPMAP1LC3B | |
| SCHEMBL13884204 | 0.90 | MAP1LC3B (0.38) | FURINFAPMAP1LC3BNPY5RNPY1R | |
| SCHEMBL26008568 | 0.89 | MAP1LC3B (0.40) | FURINHTTFAPMAP1LC3B | |
| SCHEMBL26009307 | 0.89 | MAP1LC3B (0.40) | FURINHTTFAPMAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120148608-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148608-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | FURIN 410/4885HTT 3676/4885FAP 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.